About Rezdiffra Rezdiffra is the FIRST AND ONLY
FDA-approved treatment for adults
with NASH with liver scarring,* along with diet and exercise.

*Moderate to advanced liver scarring (fibrosis) without cirrhosis.

About Rezdiffra Rezdiffra is the FIRST AND ONLY FDA-approved treatment for adults with NASH with liver scarring,* along with diet and exercise.

*Moderate to advanced liver scarring (fibrosis) without cirrhosis.

About Rezdiffra

A breakthrough treatment for adults with NASH with liver scarring.*

Rezdiffra is a prescription pill taken once per day and is the only medicine proven to help:

Reduce scarring
(fibrosis)†

REDUCE NASH‡

Quick Tip:

Rezdiffra goes hand-in-hand with a healthy diet and appropriate exercise routine. Work with your liver specialist to determine what’s right for you.

†Reduction in scarring defined as improvement in fibrosis with no worsening of steatohepatitis (defined as no increase in score for ballooning, inflammation, or steatosis).

‡Defined as resolution of steatohepatitis (score of 0-1 for inflammation, 0 for ballooning and any value for steatosis) with no worsening of liver scarring.

Study Results

How Rezdiffra can help you

Rezdiffra was studied in a large clinical trial and showed significant results at 1 year§

Helps reduce liver scarring‖

as many patients taking either 80 mg or 100 mg of Rezdiffra compared to placebo

Helps reduce NASH

as many patients taking either 80 mg or 100 mg of Rezdiffra compared to placebo

On average, liver enzymes appeared to be reduced in patients taking Rezdiffra compared to those taking placebo starting as early as 3 months through 1 year.§,‖

§Rezdiffra was assessed by 2 credible healthcare providers (A&B).

‖Improvement in liver scarring in patients taking Rezdiffra vs placebo:

  A: 28% (100 mg of Rezdiffra), 23% (80 mg of Rezdiffra) vs 15% ( placebo)

  B: 24% (100 mg of Rezdiffra), 23% (80 mg of Rezdiffra) vs 13% (placebo)

NASH resolution in patients taking Rezdiffra vs placebo:

  A: 36% (100 mg of Rezdiffra), 27% (80 mg of Rezdiffra) vs 13% (placebo)

  B: 24% (100 mg of Rezdiffra), 26% (80 mg of Rezdiffra) vs 9% (placebo)

How Rezdiffra works

Rezdiffra works right where you need it

Rezdiffra treats NASH with liver scarring* by:

Working directly in the liver

Rezdiffra is specially designed to target your liver.

Helping reduce liver fat

Rezdiffra reactivates liver cells, allowing your liver to reduce liver fat.

*Moderate to advanced liver scarring (fibrosis) without cirrhosis.

How do I know if Rezdiffra is working?

Your liver specialist is the best person to ask. Regular visits per your specialist’s recommendations can help assess the effect of Rezdiffra on your liver.

Starting Rezdiffra

Get tips on how to get the most out of your treatment.

Taking Rezdiffra

Stay informed

Get the latest information about Rezdiffra and NASH with scarring, plus ongoing support and resources, right in your inbox.

Sign up!

Get the most out of your next specialist appointment

Download and print one of our guides to help you have a more productive conversation with your liver specialist.

Download Doctor Discussion Guide
Download Doctor Discussion Guide

Important Safety Information and Indication

Before you take Rezdiffra, tell your healthcare provider about all of your medical conditions, including if you:

  • have any liver problems other than NASH.
  • have gallbladder problems or have been told you have gallbladder problems, including gallstones.
  • are pregnant or plan to become pregnant. It is not known if Rezdiffra will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if Rezdiffra passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Rezdiffra.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

  • Rezdiffra and other medicines may affect each other, causing side effects. Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works.
  • Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help lower your triglycerides, or cyclosporine to suppress your immune system, because Rezdiffra is not recommended in patients taking these medicines.
  • Tell your healthcare provider if you are taking medicines such as clopidogrel to thin your blood or statin medicines to help lower your cholesterol.
  • Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

What are the possible side effects of Rezdiffra?

Rezdiffra may cause serious side effects, including:

  • liver injury (hepatotoxicity). Stop taking Rezdiffra and call your healthcare provider right away if you develop the following signs or symptoms of hepatotoxicity, including tiredness, nausea, vomiting, fever, rash, your skin or the white part of your eyes turns yellow (jaundice), or stomach pain/tenderness.
  • gallbladder problems. Gallbladder problems such as gallstones, or inflammation of the gallbladder, or inflammation of the pancreas from gallstones can occur with NASH and may occur if you take Rezdiffra. Call your healthcare provider right away if you develop any signs or symptoms of these conditions, including nausea, vomiting, fever, or pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen to your back and the pain may happen with or without vomiting.

The most common side effects of Rezdiffra include diarrhea, nausea, itching, stomach pain, vomiting, dizziness, and constipation.

These are not all the possible side effects of Rezdiffra. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Madrigal Pharmaceuticals, Inc. at 1-800-905-0324.

What is Rezdiffra?

Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.

This indication is approved based on improvement of NASH and liver scarring (fibrosis). There are ongoing studies to confirm the clinical benefit of Rezdiffra.

Please see the full Prescribing Information, including Patient Information, for Rezdiffra.